Calcium entry blockers in the treatment of hypertension

Current status and future prospects

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Calcium entry blockers will be increasingly used for the treatment of hypertension. The currently available calcium entry blockers are similar in antihypertensive efficacy but differ in their effects on the atrioventricular node and the degree of peripheral vasodilatory action. The new generation of dihydropyridine calcium entry blockers exhibits more specific vasodilatory actions with a less negative inotropic effect, which may affect their use in patients with congestive heart failure. The responsiveness to these drugs is little affected by race or age. Because of their mild natriuretic action, the concomitant use of dietary sodium restriction or diuretics may be less necessary. Short-term administration of calcium entry blockers preserves or improves renal function; however, their long-term effect has not been documented. Calcium entry blockers have not exhibited protection against coronary heart disease, but experimental evidence supports the continued search for cardioprotection. Calcium entry blockers are important drugs for the treatment of hypertension; the second generation may provide additional benefits because of its more specific pharmacologic actions.

Original languageEnglish (US)
Pages (from-to)817-823
Number of pages7
JournalJournal of the American Medical Association
Volume262
Issue number6
StatePublished - Aug 11 1989

Fingerprint

Hypertension
Calcium
Therapeutics
Pharmacologic Actions
Dietary Sodium
Atrioventricular Node
Diuretics
Pharmaceutical Preparations
Antihypertensive Agents
Coronary Disease
Heart Failure
Kidney

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Calcium entry blockers in the treatment of hypertension : Current status and future prospects. / Kaplan, Norman M.

In: Journal of the American Medical Association, Vol. 262, No. 6, 11.08.1989, p. 817-823.

Research output: Contribution to journalArticle

@article{a25004da23f543e8a367354ea363bf87,
title = "Calcium entry blockers in the treatment of hypertension: Current status and future prospects",
abstract = "Calcium entry blockers will be increasingly used for the treatment of hypertension. The currently available calcium entry blockers are similar in antihypertensive efficacy but differ in their effects on the atrioventricular node and the degree of peripheral vasodilatory action. The new generation of dihydropyridine calcium entry blockers exhibits more specific vasodilatory actions with a less negative inotropic effect, which may affect their use in patients with congestive heart failure. The responsiveness to these drugs is little affected by race or age. Because of their mild natriuretic action, the concomitant use of dietary sodium restriction or diuretics may be less necessary. Short-term administration of calcium entry blockers preserves or improves renal function; however, their long-term effect has not been documented. Calcium entry blockers have not exhibited protection against coronary heart disease, but experimental evidence supports the continued search for cardioprotection. Calcium entry blockers are important drugs for the treatment of hypertension; the second generation may provide additional benefits because of its more specific pharmacologic actions.",
author = "Kaplan, {Norman M}",
year = "1989",
month = "8",
day = "11",
language = "English (US)",
volume = "262",
pages = "817--823",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Calcium entry blockers in the treatment of hypertension

T2 - Current status and future prospects

AU - Kaplan, Norman M

PY - 1989/8/11

Y1 - 1989/8/11

N2 - Calcium entry blockers will be increasingly used for the treatment of hypertension. The currently available calcium entry blockers are similar in antihypertensive efficacy but differ in their effects on the atrioventricular node and the degree of peripheral vasodilatory action. The new generation of dihydropyridine calcium entry blockers exhibits more specific vasodilatory actions with a less negative inotropic effect, which may affect their use in patients with congestive heart failure. The responsiveness to these drugs is little affected by race or age. Because of their mild natriuretic action, the concomitant use of dietary sodium restriction or diuretics may be less necessary. Short-term administration of calcium entry blockers preserves or improves renal function; however, their long-term effect has not been documented. Calcium entry blockers have not exhibited protection against coronary heart disease, but experimental evidence supports the continued search for cardioprotection. Calcium entry blockers are important drugs for the treatment of hypertension; the second generation may provide additional benefits because of its more specific pharmacologic actions.

AB - Calcium entry blockers will be increasingly used for the treatment of hypertension. The currently available calcium entry blockers are similar in antihypertensive efficacy but differ in their effects on the atrioventricular node and the degree of peripheral vasodilatory action. The new generation of dihydropyridine calcium entry blockers exhibits more specific vasodilatory actions with a less negative inotropic effect, which may affect their use in patients with congestive heart failure. The responsiveness to these drugs is little affected by race or age. Because of their mild natriuretic action, the concomitant use of dietary sodium restriction or diuretics may be less necessary. Short-term administration of calcium entry blockers preserves or improves renal function; however, their long-term effect has not been documented. Calcium entry blockers have not exhibited protection against coronary heart disease, but experimental evidence supports the continued search for cardioprotection. Calcium entry blockers are important drugs for the treatment of hypertension; the second generation may provide additional benefits because of its more specific pharmacologic actions.

UR - http://www.scopus.com/inward/record.url?scp=0024402814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024402814&partnerID=8YFLogxK

M3 - Article

VL - 262

SP - 817

EP - 823

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 6

ER -